These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 16406914)

  • 21. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
    Naslund M; Eaddy MT; Hogue SL; Kruep EJ; Shah MB
    Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How frequent are invasive therapies required in patients receiving tamsulosin for benign prostatic hyperplasia? A retrospective long-term study.
    Kawabe K; Homma Y; Kubota K; Sozu T;
    Int J Urol; 2006 Feb; 13(2):127-31. PubMed ID: 16563136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term results of medical treatment in benign prostatic hyperplasia.
    Kim CI; Chang HS; Kim BK; Park CH
    Urology; 2006 Nov; 68(5):1015-9. PubMed ID: 17095071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contemporary patients with LUTS/BPH requiring prostatectomy have long-term history of treatment with alpha1-blockers and large prostates compared with past cases.
    Takeuchi M; Masumori N; Tsukamoto T
    Urology; 2009 Sep; 74(3):606-9. PubMed ID: 19586655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Definition of at-risk patients: baseline variables.
    Roehrborn CG
    BJU Int; 2006 Apr; 97 Suppl 2():7-11; discussion 21-2. PubMed ID: 16507046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo.
    Crawford ED; Wilson SS; McConnell JD; Slawin KM; Lieber MC; Smith JA; Meehan AG; Bautista OM; Noble WR; Kusek JW; Nyberg LM; Roehrborn CG;
    J Urol; 2006 Apr; 175(4):1422-6; discussion 1426-7. PubMed ID: 16516013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polymorphisms in the alpha1A-adrenoceptor gene do not modify the short- and long-term efficacy of alpha1-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia.
    Mochtar CA; Laan W; Van Houwelingen KP; Franke B; De La Rosette JJ; Schalken JA; Kiemeney LA
    BJU Int; 2006 Apr; 97(4):852-5. PubMed ID: 16536786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
    Roehrborn CG
    BJU Int; 2006 Apr; 97(4):734-41. PubMed ID: 16536764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Durability and cost-effectiveness of transurethral needle ablation of the prostate as an alternative to transurethral resection of the prostate when alpha-adrenergic antagonist therapy fails.
    Rosario DJ; Phillips JT; Chapple CR
    J Urol; 2007 Mar; 177(3):1047-51; discussion 1051. PubMed ID: 17296409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Post-void residual urine as a predictor of urinary tract infection--is there a cutoff value in asymptomatic men?
    May M; Brookman-Amissah S; Hoschke B; Gilfrich C; Braun KP; Kendel F
    J Urol; 2009 Jun; 181(6):2540-4. PubMed ID: 19375097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Watchful waiting in benign prostatic hyperplasia.
    Wiygul J; Babayan RK
    Curr Opin Urol; 2009 Jan; 19(1):3-6. PubMed ID: 19057209
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Change in International Prostate Symptom Score, prostrate-specific antigen and prostate volume in patients with benign prostatic hyperplasia followed longitudinally.
    Tsukamoto T; Masumori N; Rahman M; Crane MM
    Int J Urol; 2007 Apr; 14(4):321-4; discussion 325. PubMed ID: 17470162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natural course of lower urinary tract symptoms following discontinuation of alpha-1-adrenergic blockers in patients with benign prostatic hyperplasia.
    Yokoyama T; Watanabe T; Saika T; Nasu Y; Kumon H; Miyaji Y; Nagai A
    Int J Urol; 2007 Jul; 14(7):598-601. PubMed ID: 17645601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater.
    Kaplan SA; McConnell JD; Roehrborn CG; Meehan AG; Lee MW; Noble WR; Kusek JW; Nyberg LM;
    J Urol; 2006 Jan; 175(1):217-20; discussion 220-1. PubMed ID: 16406915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement.
    Gittelman M; Ramsdell J; Young J; McNicholas T
    J Urol; 2006 Sep; 176(3):1045-50; discussion 1050. PubMed ID: 16890688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Morrill B; Montorsi F;
    J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ; Miner M
    Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between chronic kidney disease and small residual urine volumes in patients with benign prostatic hyperplasia.
    Yamasaki T; Naganuma T; Iguchi T; Kuroki Y; Kuwabara N; Takemoto Y; Shoji T; Nakatani T
    Nephrology (Carlton); 2011 Mar; 16(3):335-9. PubMed ID: 21126286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between lower urinary tract symptoms and objective measures of benign prostatic hyperplasia: a Chinese survey.
    Wang JY; Liu M; Zhang YG; Zeng P; Ding Q; Huang J; He DL; Song B; Kong CZ; Pang J
    Chin Med J (Engl); 2008 Oct; 121(20):2042-5. PubMed ID: 19080272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Study on patients with benign prostate hyperplasia treated by the therapeutic regimen of watchful waiting during a twenty-four-month follow-up period].
    Zhang YG; Wang JY; Liu M; Xu J; Wu JY; Xin Y; Wan B; Wei D; Zhu SC; Zeng P
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun; 29(6):611-3. PubMed ID: 19040049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.